| Today's Big NewsJun 15, 2023 |
| By Kevin Dunleavy An announcement early this month by Mark Cuban’s deep discount drug company that it would sell Coherus Biosciences’ biosimilar version of AbbVie’s Humira has the Illinois drugmaker calling foul. In a regulatory filing, AbbVie claims that Coherus has violated a licensing agreement, which governs the commercializing of the biosimilar. |
|
|
|
By Max Bayer Mersana Therapeutics' lead antibody-drug conjugate (ADC) has had the clamps put down by the FDA over bleeding events in patients that have included five fatalities. |
By Zoey Becker Sandoz' Act4Biosimilars action plan includes a detailed report of challenges preventing wider biosimilar access in each region, starting with the Americas. The initiative's steering group will work with stakeholders across the region to implement steps to boost uptake. |
By Nick Paul Taylor Eli Lilly is joining Amgen and Novartis in the pack of drugmakers aiming to treat cardiovascular disease by targeting lipoprotein(a) (Lp(a)). The Big Pharma landed a spot at the back of the bunch by handing Verve Therapeutics $60 million for rights to its once-and-done gene editing approach to the problem protein. |
|
Wednesday, June 28, 2023 11:00am ET / 8:00am PT Join us for this this insightful webinar to learn how antibody profiling has been used to successfully identify novel diagnostic, prognostic, therapeutic, and predictive biomarkers in melanoma, prostate cancer, breast cancer, ovarian cancer, and rare cancers, yielding promising results.
|
|
By Eric Sagonowsky While demand for COVID-19 vaccines has plummeted throughout 2023, healthcare officials remain focused on ensuring that the most effective shots are available for those who need them. Now, regulators are discussing strain selection for the next round of boosters. |
By James Waldron Aldeyra Therapeutics has notched up another phase 3 win for its allergic conjunctivitis treatment, as the biotech awaits an FDA approval decision for dry eye disease. |
By Angus Liu After acing a study for the induction treatment of ulcerative colitis, AbbVie’s Skyrizi has delivered another win in a maintenance trial. An approval now looks within reach for 2024. |
By Nick Paul Taylor Astellas has found a biotech capable of enhancing its in-house protein degradation skills. Having used its internal capabilities to hustle a KRAS candidate into the clinic, the Japanese drugmaker has agreed to pay Cullgen $35 million upfront to access next-generation prospects. |
Fierce podcastsDon't miss an episode |
| | This week on "The Top Line," we discuss the the top news from this year's annual ASCO meeting, plus contesting the Inflation Reduction Act, an ADHD video game, and the rest of the week's headlines. |
|
|---|
|
|
|
Monday, June 26, 2023 | 11:00 am ET Join us for a webinar on “The RESTORE Trial: First-Ever Lab-Grown RBCs” where Dr. Ashley Toye will talk about the first-ever clinical trial conducted for the transfusion of lab-grown red blood cells. Register now. |
|
| WhitepaperAutoantibody screening is promising for early cancer detection with the potential to improve the whole treatment decision tree, providing a less invasive, powerful approach. Sponsored by: Sengenics |
| WhitepaperExplore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
| WhitepaperDiscover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| eBookSee how clinical trial sponsors can build stronger strategies to address challenges across the patient enrollment funnel, starting with four necessary steps. Sponsored by: OneStudyTeam |
| WhitepaperThis paper outlines various market archetypes and key considerations leaders must address when prioritizing new potential markets for gene therapies. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| ResearchWhat role do the Library and Legal teams play in the drug development pipeline at Lilly? An import one – find out how. Sponsored by: CCC |
| |
|
